BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luck JN, Tettelin H, Orihuela CJ. Sugar-Coated Killer: Serotype 3 Pneumococcal Disease. Front Cell Infect Microbiol 2020;10:613287. [PMID: 33425786 DOI: 10.3389/fcimb.2020.613287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Liatsikos K, Hyder-Wright A, Pojar S, Chen T, Wang D, Davies K, Myerscough C, Reine J, Robinson RE, Urban B, Mitsi E, Solorzano C, Gordon SB, Quinn A, Pan K, Anderson AS, Theilacker C, Begier E, Gessner BD, Collins A, Ferreira DM; PNEUMO 2 study group. Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2). BMJ Open 2022;12:e062109. [PMID: 35798520 DOI: 10.1136/bmjopen-2022-062109] [Reference Citation Analysis]
2 Shirley M. 20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults. Drugs. [DOI: 10.1007/s40265-022-01733-z] [Reference Citation Analysis]
3 Waz NT, Oliveira S, Girardello R, Lincopan N, Barazzone G, Parisotto T, Hakansson AP, Converso TR, Darrieux M. Influence of the Polysaccharide Capsule on the Bactericidal Activity of Indolicidin on Streptococcus pneumoniae. Front Microbiol 2022;13:898815. [DOI: 10.3389/fmicb.2022.898815] [Reference Citation Analysis]
4 Gingerich AD, Mousa JJ. Diverse Mechanisms of Protective Anti-Pneumococcal Antibodies. Front Cell Infect Microbiol 2022;12:824788. [DOI: 10.3389/fcimb.2022.824788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Brissac T, Martínez E, Kruckow KL, Riegler AN, Ganaie F, Im H, Bakshi S, Arroyo-Diaz NM, Spencer BL, Saad JS, Nahm MH, Orihuela CJ. Capsule Promotes Intracellular Survival and Vascular Endothelial Cell Translocation during Invasive Pneumococcal Disease. mBio 2021;12:e0251621. [PMID: 34634940 DOI: 10.1128/mBio.02516-21] [Reference Citation Analysis]
6 Mokaddas E, Syed S, Albert MJ. The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019. Hum Vaccin Immunother 2021;:1-6. [PMID: 34435932 DOI: 10.1080/21645515.2021.1968216] [Reference Citation Analysis]
7 Walkowski W, Bassett J, Bhalla M, Pfeifer BA, Ghanem ENB. Intranasal Vaccine Delivery Technology for Respiratory Tract Disease Application with a Special Emphasis on Pneumococcal Disease. Vaccines (Basel) 2021;9:589. [PMID: 34199398 DOI: 10.3390/vaccines9060589] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Ozdilek A, Huang J, Babb R, Paschall AV, Middleton DR, Duke JA, Pirofski LA, Mousa JJ, Avci FY. A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies. mBio 2021;12:e0080021. [PMID: 34061603 DOI: 10.1128/mBio.00800-21] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Esposito S, Dal Canto G, Caramia MR, Fainardi V, Pisi G, Principi N. Complications in community acquired pneumonia: magnitude of problem, risk factors, and management in pediatric age. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 33971782 DOI: 10.1080/14787210.2021.1927710] [Reference Citation Analysis]
10 Principi N, Esposito S. Pneumococcal Disease Prevention: Are We on the Right Track? Vaccines (Basel) 2021;9:305. [PMID: 33804822 DOI: 10.3390/vaccines9040305] [Reference Citation Analysis]
11 Scott NR, Mann B, Tuomanen EI, Orihuela CJ. Multi-Valent Protein Hybrid Pneumococcal Vaccines: A Strategy for the Next Generation of Vaccines. Vaccines (Basel) 2021;9:209. [PMID: 33801372 DOI: 10.3390/vaccines9030209] [Reference Citation Analysis]